Cardiac monitoring and incidence of cardiotoxicity cardiomyopathy among breast cancer patients undergoing anthracycline regimen chemotherapy: insight from a single centre study

Abstract Background Anthracyclines remain a cornerstone of breast cancer therapy but carry a significant risk of cancer therapy-related cardiac dysfunction (CTRCD). This study evaluates the incidence of CTRCD in an Indonesian setting using the latest 2022 ESC Cardio-Oncology guidelines, focusing on subclinical markers such as hs-Troponin I, Global Longitudinal Strain (GLS) and Mechanical Dispersion (MD). Methods This retrospective analytical study involved 98 breast cancer patients treated with anthracyclines at a top-tier referral hospital in Indonesia from July 2018 to February 2020. Clinical assessments, hs-Troponin I, and echocardiography (LVEF, GLS, and MD) were performed at baseline, 1, 3, and 6 months. CTRCD was defined per the 2022 ESC criteria. Results CTRCD occurred in 74.5% of patients, predominantly as asymptomatic mild cases (63.26%). While symptomatic CTRCD was relatively low (7.14%), asymptomatic dysfunction was detected as early as one month post-chemotherapy. A significant progressive decline was observed in LVEF (68.2 ± 6.2% to 61.3 ± 8.8%, p < 0.001) and GLS (-19.7 ± 2.9% to -17.1 ± 3.5%, p < 0.001). Notably, mechanical dispersion significantly increased over time (p = 0.029), and median hs-Troponin I surged from 1.6 ng/L to 82.2 ng/L (p < 0.001) by month 6. Conclusion The high incidence of asymptomatic CTRCD underscores the inadequacy of relying on clinical symptoms alone. Integration of hs-troponin, GLS, and mechanical dispersion monitoring is essential for early detection, enabling timely cardioprotective intervention.